Legend Biotech
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Legend Biotech generated cash of -$393,276,000, which is less than the previous year. Cash used in financing activities reached the amount of $791,490,000 last year. Net change in cash is therefore $491,682,000.
Cash Flow
| 2017 | -2.37M | -827K | 3.32M |
|---|---|---|---|
| 2018 | 307.68M | -102.25M | 2.50M |
| 2019 | -83.06M | -58.65M | 14.66M |
| 2020 | -223.00M | -24.16M | 618.87M |
| 2021 | -198.46M | -194.98M | 626.66M |
| 2022 | -200.02M | -78.34M | 377.97M |
| 2023 | -393.27M | 92.78M | 791.49M |
LEGN Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 786.03M | 688.93M | 455.68M | 83.36M | 210.16M | 2.11M | 1.98M |
Operating activities | |||||||
Net income | -518.25M | -445.72M | -386.20M | -307.62M | -130.37M | -1.61M | 9.36M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 20.45M | 18.39M | 13.91M | 9.93M | 5.26M | 1.68M | 217K |
Stock-based compensation expense | 47.68M | 34.33M | 20.15M | 4.76M | 1.27M | 0 | 0 |
| Deferred income tax benefit | 47.68M | 34.33M | 20.15M | 4.76M | 1.27M | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | -98.98M | 50.32M | 24.59M | -45M | -3.77M | 207.60M | -228.06M |
Inventories | -12.70M | -8.60M | 51K | -643K | -22K | -1.12M | -5.99K |
Accounts payable | -12.70M | 25.85M | 1.80M | -4.34M | 2.01M | 3.23M | 4.17M |
Cash generated by operating activities | -393.27M | -200.02M | -198.46M | -223.00M | -83.06M | 307.68M | -2.37M |
Investing activities | |||||||
Purchases Of Investments | -4.86B | -654.97M | -377.95M | -72.68M | -390.39M | -6M | 0 |
Investments In Property Plant And Equipment | -20.08M | -22.27M | -47.11M | -49.77M | -39.17M | -21.02M | -887K |
Acquisitions Net | 0 | 0 | 3.20M | 4.02M | -460K | 0 | 60K |
Cash generated by investing activities | 92.78M | -78.34M | -194.98M | -24.16M | -58.65M | -102.25M | -827K |
Financing activities | |||||||
Common Stock Issued | 583.68M | 377.64M | 623.44M | 462.08M | 0 | 0 | 1.42M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -3.75M | -2.59M | -1.41M | -2.60M | -5.05M | -219K | -32K |
Cash used in financing activities | 791.49M | 377.97M | 626.66M | 618.87M | 14.66M | 2.50M | 3.32M |
Net Change In Cash | 491.68M | 97.09M | 233.24M | 372.32M | -126.80M | 208.05M | 128K |
Cash at end of period | 1.27B | 786.03M | 688.93M | 455.68M | 83.36M | 210.16M | 2.11M |
| Data source | Data source | Data source | Data source |